These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 37808197)

  • 1. Optimization of small molecule degraders and antagonists for targeting estrogen receptor based on breast cancer: current status and future.
    Yao J; Tao Y; Hu Z; Li J; Xue Z; Zhang Y; Lei Y
    Front Pharmacol; 2023; 14():1225951. PubMed ID: 37808197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective estrogen receptor degraders (SERDs) and covalent antagonists (SERCAs): a patent review (2015-present).
    Scott JS; Barlaam B
    Expert Opin Ther Pat; 2022 Feb; 32(2):131-151. PubMed ID: 34763600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective estrogen receptor degraders (SERDs) and covalent antagonists (SERCAs): a patent review (July 2021-December 2023).
    Scott JS; Klinowska TCM
    Expert Opin Ther Pat; 2024 May; 34(5):333-350. PubMed ID: 38836316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment.
    Patel HK; Bihani T
    Pharmacol Ther; 2018 Jun; 186():1-24. PubMed ID: 29289555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel scaffold long-acting selective estrogen receptor antagonist and degrader with superior preclinical profile against ER+ breast cancer.
    Wang B; Ma M; Dai Y; Yu P; Ye L; Wang W; Sha C; Yang H; Yang Y; Zhu Y; Dong L; Wei S; Wang L; Tian J; Wang H
    Eur J Med Chem; 2024 Jan; 264():115934. PubMed ID: 38007911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.
    Lai A; Kahraman M; Govek S; Nagasawa J; Bonnefous C; Julien J; Douglas K; Sensintaffar J; Lu N; Lee KJ; Aparicio A; Kaufman J; Qian J; Shao G; Prudente R; Moon MJ; Joseph JD; Darimont B; Brigham D; Grillot K; Heyman R; Rix PJ; Hager JH; Smith ND
    J Med Chem; 2015 Jun; 58(12):4888-904. PubMed ID: 25879485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the Estrogen Receptor for the Treatment of Breast Cancer: Recent Advances and Challenges.
    Rej RK; Thomas JE; Acharyya RK; Rae JM; Wang S
    J Med Chem; 2023 Jul; 66(13):8339-8381. PubMed ID: 37377342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral Selective Estrogen Receptor Degraders (SERDs) in Breast Cancer: Advances, Challenges, and Current Status.
    Downton T; Zhou F; Segara D; Jeselsohn R; Lim E
    Drug Des Devel Ther; 2022; 16():2933-2948. PubMed ID: 36081610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The race to develop oral SERDs and other novel estrogen receptor inhibitors: recent clinical trial results and impact on treatment options.
    Wang Y; Tang SC
    Cancer Metastasis Rev; 2022 Dec; 41(4):975-990. PubMed ID: 36229710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Next-generation selective estrogen receptor degraders and other novel endocrine therapies for management of metastatic hormone receptor-positive breast cancer: current and emerging role.
    Lloyd MR; Wander SA; Hamilton E; Razavi P; Bardia A
    Ther Adv Med Oncol; 2022; 14():17588359221113694. PubMed ID: 35923930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and biological evaluation of fluorinated selective estrogen receptor degraders (FSERDs) --- A promising strategy for advanced ER positive breast cancer.
    Lu Y; Liu C; Wang X; Liu L; Zhao Z; Liang Z; Liu Y; Wen Z; Du Q; Liu W
    Eur J Med Chem; 2023 May; 253():115324. PubMed ID: 37019030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective Estrogen Receptor Degraders (SERDs): A Promising Strategy for Estrogen Receptor Positive Endocrine-Resistant Breast Cancer.
    Lu Y; Liu W
    J Med Chem; 2020 Dec; 63(24):15094-15114. PubMed ID: 33138369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New steps on an old path: Novel estrogen receptor inhibitors in breast cancer.
    Pagliuca M; Donato M; D'Amato AL; Rosanova M; Russo AOM; Scafetta R; De Angelis C; Trivedi MV; André F; Arpino G; Del Mastro L; De Laurentiis M; Puglisi F; Giuliano M
    Crit Rev Oncol Hematol; 2022 Dec; 180():103861. PubMed ID: 36374739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SAR439859, a Novel Selective Estrogen Receptor Degrader (SERD), Demonstrates Effective and Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models.
    Shomali M; Cheng J; Sun F; Koundinya M; Guo Z; Hebert AT; McManus J; Levit MN; Hoffmann D; Courjaud A; Arrebola R; Cao H; Pollard J; Lee JS; Besret L; Caron A; Bangari DS; Abecassis PY; Schio L; El-Ahmad Y; Halley F; Tabart M; Certal V; Thompson F; McCort G; Filoche-Rommé B; Cheng H; Garcia-Echeverria C; Debussche L; Bouaboula M
    Mol Cancer Ther; 2021 Feb; 20(2):250-262. PubMed ID: 33310762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral selective estrogen receptor degraders (SERDs): The new emperors in breast cancer clinical practice?
    Ferro A; Generali D; Caffo O; Caldara A; De Lisi D; Dipasquale M; Lorenzi M; Monteverdi S; Fedele P; Ciribilli Y
    Semin Oncol; 2023; 50(3-5):90-101. PubMed ID: 37673696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective Estrogen receptor degraders (SERDs) for the treatment of breast cancer: An overview.
    Bhatia N; Hazra S; Thareja S
    Eur J Med Chem; 2023 Aug; 256():115422. PubMed ID: 37163948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Latest generation estrogen receptor degraders for the treatment of hormone receptor-positive breast cancer.
    Chen YC; Yu J; Metcalfe C; De Bruyn T; Gelzleichter T; Malhi V; Perez-Moreno PD; Wang X
    Expert Opin Investig Drugs; 2022 Jun; 31(6):515-529. PubMed ID: 34694932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimization of an indazole series of selective estrogen receptor degraders: Tumor regression in a tamoxifen-resistant breast cancer xenograft.
    Govek SP; Nagasawa JY; Douglas KL; Lai AG; Kahraman M; Bonnefous C; Aparicio AM; Darimont BD; Grillot KL; Joseph JD; Kaufman JA; Lee KJ; Lu N; Moon MJ; Prudente RY; Sensintaffar J; Rix PJ; Hager JH; Smith ND
    Bioorg Med Chem Lett; 2015 Nov; 25(22):5163-7. PubMed ID: 26463130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral SERD, a Novel Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer.
    Neupane N; Bawek S; Gurusinghe S; Ghaffary EM; Mirmosayyeb O; Thapa S; Falkson C; O'Regan R; Dhakal A
    Cancers (Basel); 2024 Jan; 16(3):. PubMed ID: 38339371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical use of selective estrogen receptor modulators and down regulators with the main focus on breast cancer.
    Baumann CK; Castiglione-Gertsch M
    Minerva Ginecol; 2009 Dec; 61(6):517-39. PubMed ID: 19942839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.